Risk factors for postoperative venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis
Jie Fu, Yiyi Zhou, Feng Zhang, Ru Lv, Lu Hu, Haiyan Zhang
TL;DR
This study identifies key risk factors for blood clots after lung cancer surgery, which could help improve patient outcomes through targeted prevention.
Contribution
The study provides a comprehensive meta-analysis of risk factors for postoperative venous thromboembolism in lung cancer patients.
Findings
Age ≥ 65 years is a significant risk factor for VTE after lung cancer surgery.
Thoracotomy and prolonged operation time (≥ 2 hours) increase VTE risk.
Preoperative chemotherapy and abnormal D-dimer levels are linked to higher VTE occurrence.
Abstract
Venous thromboembolism (VTE) is a serious complication following lung cancer surgery, which not only complicates treatment but may also delay cancer-specific therapies and even threaten patient survival. Currently, the risk factors for postoperative VTE in lung cancer patients remain unclear. Therefore, we conducted a meta-analysis to identify risk factors associated with VTE in these patients after surgery. We systematically searched PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Biomedical Literature Database (CBM), and VIP Database for studies investigating risk factors for VTE after lung cancer surgery. The search covered the period from database inception to February 2025. Two reviewers independently screened the literature based on the inclusion and exclusion criteria, extracted data, and assessed the…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Figure 14
Figure 15
Figure 16
Figure 17
Figure 18
Figure 19
Figure 20
Figure 21
Figure 22| Study, year | Country | Study design | Type of VTE | Sample size | Number of VTE cases | Male,n(%) | Age(Mean) | NOS score | Risk factor |
|---|---|---|---|---|---|---|---|---|---|
| Akhtar-Danesh et al. ( | Canada | Case–control study | VTE | 12,626 | 345 | 5,923(46.91%) | NR | 9 | ①②⑥⑧⑨⑩⑪ |
| Awang et al. ( | China | Case–control study | DVT | 108 | 36 | 64(59.26%) | 65.7 | 9 | ①⑤⑧⑩⑪⑫⑬⑰ |
| Cui et al. ( | China | Case–control study | VTE | 339 | 39 | 166(48.98%) | 60.1 | 8 | ①③⑥⑧⑨⑩⑪⑫⑮ |
| Ding et al. ( | China | Case–control study | VTE | 601 | 63 | 289(48.09%) | 61 | 9 | ①③⑤⑧⑩⑪⑫⑯⑰ |
| Dong et al. ( | China | Case–control study | VTE | 132 | 11 | 42(31.82%) | 51 | 8 | ①③④⑥⑦⑨ |
| Dong et al. ( | China | Cohort study | VTE | 314 | 23 | 117(37.26%) | 57 | 7 | ①③④⑥⑦⑧⑨⑩⑪⑫⑮⑯⑱ |
| Du et al. ( | China | Case–control study | DVT | 83 | 25 | 51(61.45%) | NR | 7 | ①②③⑤⑥⑧⑩⑪⑫⑮ |
| Hei et al. ( | China | Case–control study | PE | 90 | 45 | 54(60.00%) | 58.6 | 7 | ①③④⑥⑧⑩⑪⑬⑭ |
| Jia et al. ( | China | Case–control study | DVT | 403 | 54 | 262(65.01%) | 59 | 8 | ①③④⑧⑩⑪⑬⑭⑱ |
| Ke et al. ( | China | Case–control study | VTE | 160 | 43 | 73(45.63%) | NR | 8 | ①②③④⑤⑥⑨⑬ |
| Li et al. ( | China | Cohort study | PE | 9,726 | 55 | 5,326(54.76%) | 66.5 | 7 | ①⑧⑩⑪⑫⑯ |
| Qiao et al. ( | China | Case–control study | DVT | 222 | 74 | 139(62.61%) | 60.04 | 8 | ①⑧⑩⑪⑫⑯⑰ |
| Qin ( | China | Case–control study | VTE | 227 | 63 | 85(37.44%) | 56.99 | 7 | ①③④⑥⑧⑩⑪⑮ |
| Qin et al. ( | China | Case–control study | VTE | 502 | 138 | 171(34.06%) | 56.99 | 7 | ③④⑥ |
| Song et al. ( | China | Cohort study | VTE | 262 | 30 | 149(56.87%) | 54.73 | 8 | ①⑤⑥⑫⑯ |
| Thomas et al. ( | America | Case–control study | VTE | 14,308 | 234 | 6,630(46.34%) | NR | 9 | ①②③⑤⑥⑫⑯ |
| Wang ( | China | Case–control study | VTE | 354 | 50 | 188(53.11%) | 62.4 | 7 | ①③⑥⑧⑨⑩⑪⑫ |
| Wu et al. ( | China | Case–control study | VTE | 84 | 18 | 46(54.76%) | 60.75 | 7 | ①②③④⑥⑧⑨⑩⑪⑰⑱ |
| Yang et al. ( | China | Case–control study | VTE | 1,001 | 53 | 656(65.53%) | NR | 7 | ①②⑧⑩⑪⑰⑱ |
| Zhang et al. ( | China | Case–control study | VTE | 118 | 59 | 74(62.71%) | 61.5 | 8 | ①⑥⑧⑨⑮ |
| Zhou et al. ( | China | Case–control study | DVT | 120 | 60 | 76(63.33%) | 70.07 | 7 | ①⑤⑦⑬ |
| Outcomes |
| Pooled analysis results | Change model analysis results | |||||
|---|---|---|---|---|---|---|---|---|
| Model | OR (95% CI) | Model | OR (95% Cl) | |||||
| Sex (Male) | 33% | 0.080 | Random | 1.09 (0.93, 1.28) | 0.300 | Fixed |
|
|
| Age (≥ 60 years) | 84% | 0.0003 | Random | 1.74 (0.76, 3.95) | 0.190 | Fixed | 1.20 (0.95, 1.53) | 0.130 |
| Age (≥ 65 years) | 11% | 0.290 | Fixed |
|
| Random |
|
|
| Smoking history | 51% | 0.020 | Random | 1.13 (0.86, 1.49) | 0.390 | Fixed | 1.01 (0.85, 1.19) | 0.940 |
| Drinking history | 39% | 0.120 | Fixed | 1.27 (0.93, 1.75) | 0.140 | Random | 1.34 (0.88, 2.04) | 0.180 |
| BMI (≥ 25 kg/m2) | 7% | 0.370 | Fixed | 1.03 (0.84, 1.27) | 0.780 | Random | 1.02 (0.81, 1.28) | 0.860 |
| Hypertension history | 51% | 0.010 | Random | 1.30 (1.00, 1.68) | 0.050 | Fixed |
|
|
| Hyperlipidemia | 0 | 0.620 | Fixed |
|
| Random |
|
|
| Tumor stage | 81% | <0.00001 | Random |
|
| Fixed |
|
|
| Coronary heart disease | 0 | 0.490 | Fixed | 1.16 (0.83, 1.62) | 0.390 | Random | 1.16 (0.83, 1.62) | 0.390 |
| Diabetes | 59% | 0.003 | Random | 1.32 (0.96, 1.81) | 0.090 | Fixed |
|
|
| Adenocarcinoma | 20% | 0.230 | Fixed | 0.87 (0.74, 1.02) | 0.080 | Random | 0.89 (0.73, 1.09) | 0.270 |
| Thoracotomy | 25% | 0.210 | Fixed |
|
| Random |
|
|
| Operative time (≥ 3 h) | 92% | <0.00001 | Random | 1.59 (1.01, 2.50) | 0.050 | Fixed |
|
|
| Operative time (≥ 2 h) | 0 | 0.520 | Fixed |
|
| Random |
|
|
| Intraoperative bleeding (≥ 200 ml) | 0 | 0.730 | Fixed |
|
| Random |
|
|
| Tumor site(Left lung) | 0 | 0.750 | Fixed | 0.95 (0.68, 1.33) | 0.770 | Random | 0.95 (0.68, 1.33) | 0.770 |
| Pulmonary lobe resection | 89% | <0.00001 | Random | 0.89 (0.47, 1.69) | 0.730 | Fixed |
|
|
| History of chemotherapy | 70% | 0.010 | Random |
|
| Fixed |
|
|
| D-dimer abnormality | 89% | <0.00001 | Random |
|
| Fixed |
|
|
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsVenous Thromboembolism Diagnosis and Management · Hepatocellular Carcinoma Treatment and Prognosis · Inflammatory Biomarkers in Disease Prognosis
Introduction
1
Lung cancer remains one of the most prevalent malignancies worldwide, with its incidence and mortality rates consistently ranking first among all cancers (1–5). For eligible patients, comprehensive treatment centered around surgery remains the primary clinical approach, as it effectively removes lesion tissues and improves survival outcomes (6, 7). However, surgical trauma in lung cancer patients can lead to coagulation dysfunction, resulting in a hypercoagulable state and altered hemorheology. Postoperative pain further impedes early mobilization (8, 9), collectively contributing to a high susceptibility to venous thromboembolism (VTE) after surgery (10). Studies have reported that the incidence of postoperative VTE in lung cancer patients ranges from approximately 7.3% to 13.9% (11). As a serious complication following lung cancer surgery, VTE not only complicates clinical management but may also delay cancer-specific treatment and even threaten patient survival (12). Therefore, identifying risk factors for VTE in these patients is crucial for improving prognosis. Although multiple studies have investigated these risk factors, their findings remain inconsistent (13–33). This study aims to evaluate the risk factors for VTE after lung cancer surgery through a meta-analysis, thereby providing evidence-based support for postoperative VTE prevention.
Methods
2
The study was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (34).
Literature search
2.1
A systematic literature search was performed across the following electronic databases: PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, the China Biomedical Literature Database (CBM), and VIP Database. The search period spanned from the inception of each database to February 2025 to identify all relevant studies investigating risk factors for VTE following lung cancer surgery. The search strategy combined Medical Subject Headings (MeSH) terms with free words, including but not limited to “lung cancer,” “venous thromboembolism,” “deep vein thrombosis,” “pulmonary embolism,” and “risk factor.” The specific search strategy used for PubMed is provided as an example in Supplementary Table S1.
Inclusion and exclusion criteria
2.2
The study eligibility criteria were defined as follows:
Inclusion criteria:
- Participants: Patients aged 18 years or older who were pathologically diagnosed with lung cancer and underwent surgical resection;
- Exposure: Investigation of risk factors for postoperative VTE;
- Outcome: A clear diagnosis of VTE confirmed by imaging examinations;
- Study design: Cohort or case–control studies.
Exclusion criteria:
- Duplicate publication;
- Studies published as case reports, conference abstracts, animal studies, reviews, etc.;
- Publications with insufficient data for extraction;
- Studies with a Newcastle–Ottawa Scale (NOS) score below 5 points.
Data extraction
2.3
Two investigators independently screened the retrieved literature, extracted data, and cross-checked their findings. Any disagreements were resolved through discussion until a consensus was reached. The extracted information included the first author, publication year, study design, sample size, VTE incidence, exposure factors examined, and reported outcomes.
Risk of bias assessment
2.4
The methodological quality and risk of bias of the included studies were assessed independently by two reviewers using the NOS. The NOS evaluates studies based on three domains: selection of study groups, comparability of groups, and ascertainment of either exposure or outcome. The total score ranges from 0 to 9 points. Studies were categorized as low (0–4 points), moderate (5–6 points), or high quality (7–9 points). Consistent with the exclusion criteria, only studies with a NOS score of 5 or higher were included in the final meta-analysis.
Statistical analysis
2.5
All meta-analyses were performed using RevMan software (version 5.4). For consistency, all outcome data were converted into odds ratios (ORs) with their corresponding 95% confidence intervals (CIs). Pooled ORs and 95% CIs were calculated for each risk factor. Heterogeneity across included studies was assessed using chi-square tests and quantified by the I^2^ statistic. A fixed-effects model was used when no significant heterogeneity was present (p ≥ 0.10 and I^2^ ≤ 50%); otherwise, a random-effects model was applied. Sensitivity analyses were conducted by alternating between the fixed- and random-effects models to evaluate the robustness of the pooled results. Publication bias was assessed using Egger’s test or funnel plots for risk factors that were reported in 10 or more studies.
Results
3
Literature retrieval results
3.1
The initial systematic search identified 7,597 potentially relevant records. Following a rigorous screening process of titles, abstracts, and full texts against the predefined inclusion and exclusion criteria, 21 studies (13–33) were ultimately included for meta-analysis (Figure 1). The included studies, conducted in the United States, China, and Canada and published between 2012 and 2024, comprised both case–control and cohort designs. Sample sizes ranged from 84 to 14,308 participants. The methodological quality assessed by the NOS was high, with scores ranging from 7 to 9. The VTE incidence rate across studies was 3.63%. The baseline characteristics of the included studies are summarized in Table 1.
Flowchart of literature selection.
Meta-analysis results
3.2
Patient factors
3.2.1
Sex
3.2.1.1
Twenty studies were included in the analysis. The meta-analysis indicated that sex was not significantly associated with the risk of VTE following lung cancer surgery (OR = 1.09, 95% CI (0.93, 1.29), p = 0.300; Figure 2).
Meta-analysis of the association between sex and postoperative venous thromboembolism in patients with lung cancer.
Age
3.2.1.2
A pooled analysis of six studies was performed to assess the influence of age. Based on four studies utilizing a threshold of 60 years, no significant association was found between age ≥ 60 years and postoperative VTE risk [OR = 1.74, 95% CI (0.76, 3.95), p = 0.190] (Figure 3). However, analysis of two studies that defined older age as ≥ 65 years identified it as a significant risk factor for VTE [OR = 1.95, 95% CI (1.45, 2.61), p < 0.00001] (Figure 4).
Meta-analysis of the association between age ≥ 60 years old and postoperative venous thromboembolism in patients with lung cancer.
Meta-analysis of the association between age ≥ 65 years old and postoperative venous thromboembolism in patients with lung cancer.
History of smoking
3.2.1.3
Thirteen studies provided data on smoking history. The meta-analysis revealed no statistically significant association between a history of smoking and the development of VTE after surgery [OR = 1.13, 95% CI (0.86, 1.49), p = 0.390] (Figure 5).
Meta-analysis of the association between smoking history and postoperative venous thromboembolism in patients with lung cancer.
Drinking history
3.2.1.4
Data from eight studies were analyzed for drinking history. The results showed no significant association between a history of drinking and postoperative VTE risk [OR = 1.27, 95% CI (0.93, 1.75), p = 0.140] (Figure 6).
Meta-analysis of the association between drinking history and postoperative venous thromboembolism in patients with lung cancer.
Body mass index (BMI)
3.2.1.5
Seven studies were included to evaluate BMI. The meta-analysis demonstrated that a BMI ≥ 25 kg/m^2^ was not significantly associated with an increased risk of VTE [OR = 1.03, 95% CI (0.84, 1.27), p = 0.780] (Figure 7).
Meta-analysis of the association between body mass index ≥ 25 kg/m2 and postoperative venous thromboembolism in patients with lung cancer.
Disease condition
3.2.2
Hypertension
3.2.2.1
Fourteen studies were included. The meta-analysis found no statistically significant association between hypertension and the risk of VTE after lung cancer surgery [OR = 1.30,95% CI (1.00,1.68), p = 0.050] (Figure 8).
Meta-analysis of the association between hypertension and postoperative venous thromboembolism in patients with lung cancer.
Hyperlipidemia
3.2.2.2
Pooled results from three studies indicated that hyperlipidemia was a significant risk factor for VTE [OR = 2.21, 95% CI (1.22, 4.02), p = 0.009] (Figure 9).
Meta-analysis of the association between hyperlipidemia and postoperative venous thromboembolism in patients with lung cancer.
Tumor staging
3.2.2.3
Analysis of 15 studies demonstrated that advanced tumor stage (III–IV) was significantly associated with an increased risk of VTE [OR = 1.76, 95%CI (1.29, 2.41), p = 0.0004] (Figure 10).
Meta-analysis of the association between tumor staging and postoperative venous thromboembolism in patients with lung cancer.
Coronary heart disease
3.2.2.4
Data from eight studies were analyzed. The meta-analysis showed that coronary heart disease was not significantly associated with VTE risk [OR = 1.16, 95%CI (0.83, 1.62), p = 0.390] (Figure 11).
Meta-analysis of the association between coronary heart disease and postoperative venous thromboembolism in patients with lung cancer.
Diabetes
3.2.2.5
Fourteen studies provided data on diabetes. No significant association was found between diabetes and postoperative VTE [OR = 1.32, 95%CI (0.96, 1.81), p = 0.090] (Figure 12).
Meta-analysis of the association between diabetes and postoperative venous thromboembolism in patients with lung cancer.
Pathological type
3.2.2.6
Based on 14 studies, the pathological type (adenocarcinoma versus other types) was not significantly associated with VTE risk [OR = 0.87, 95%CI (0.74, 1.02), p = 0.080] (Figure 13).
Meta-analysis of the association between pathological type and postoperative venous thromboembolism in patients with lung cancer.
Surgery-related factors
3.2.3
Type of surgery
3.2.3.1
Ten studies compared surgical approaches. The meta-analysis identified thoracotomy as a significant risk factor for VTE [OR = 1.76, 95% CI (1.43, 2.16), p < 0.00001] (Figure 14).
Meta-analysis of the association between the surgical approach and postoperative venous thromboembolism in patients with lung cancer.
Operation time
3.2.3.2
Five studies examined the effect of operation time. Analysis of three studies using a 3-h threshold showed no statistically significant association with VTE risk [OR = 1.59, 95%CI (1.01, 2.50), p = 0.050] (Figure 15). However, based on two studies using a 2-h threshold, an operation time ≥ 2 h was a significant risk factor [OR = 2.86, 95%CI (1.71, 4.77), p < 0.0001] (Figure 16).
Meta-analysis of the association between operation time ≥ 3 h and postoperative venous thromboembolism in patients with lung cancer.
Meta-analysis of the association between operation time ≥ 2 h and postoperative venous thromboembolism in patients with lung cancer.
Intraoperative blood loss
3.2.3.3
Two studies reported intraoperative blood loss. The meta-analysis indicated that blood loss ≥ 200 mL was a significant risk factor for VTE.
[OR = 1.13, 95%CI (1.02, 1.25), p = 0.020] (Figure 17).
Meta-analysis of the association between intraoperative bleeding and postoperative venous thromboembolism in patients with lung cancer.
Tumor site
3.2.3.4
Data from five studies showed that tumor location (left versus right lung) was not significantly associated with VTE risk [OR = 0.95, 95%CI (0.68, 1.33), p = 0.770] (Figure 18).
Meta-analysis of the association between tumor site and postoperative venous thromboembolism in patients with lung cancer.
Type of lung resection
3.2.3.5
Six studies were included. The meta-analysis found that the type of lung resection (lobectomy versus other resections) was not significantly associated with VTE risk [OR = 0.89, 95%CI (0.47, 1.69), p = 0.730] (Figure 19).
Meta-analysis of the association between type of lung resection and postoperative venous thromboembolism in patients with lung cancer.
Other factors
3.2.4
Preoperative chemotherapy
3.2.4.1
Analysis of five studies showed that preoperative chemotherapy was a significant risk factor for VTE [OR = 3.40, 95%CI (1.92, 6.02), p < 0.0001] (Figure 20).
Meta-analysis of the association between preoperative chemotherapy and postoperative venous thromboembolism in patients with lung cancer.
Abnormal D-dimer
3.2.4.2
Based on four studies, an abnormal D-dimer level was identified as a significant risk factor for VTE [OR = 2.89, 95%CI (1.50, 5.60), p = 0.002] (Figure 21).
Meta-analysis of the association between D-dimer abnormality and postoperative venous thromboembolism in patients with lung cancer.
Publication bias
3.2.5
Funnel plots were generated for factors with sufficient included studies, such as sex, pathological type, tumor stage, and hypertension. The scatter points in these funnel plots showed approximate symmetry, suggesting a low likelihood of significant publication bias (Figure 22).
Funnel plot: (A) Sex; (B) pathological type; (C) tumor stage; and (D) hypertension.
Sensitivity analysis
3.2.6
Sensitivity analysis, performed by alternating between fixed-effect and random-effects models, demonstrated that the direction and significance of the pooled results for all risk factors remained consistent. This indicates that the findings are robust and not overly dependent on the choice of statistical model (Table 2).
Discussion
4
This meta-analysis, encompassing 21 studies with a total of 41,780 participants, evaluated 18 potential risk factors for VTE following lung cancer surgery. The results identified the following significant risk factors: age ≥ 65 years, hyperlipidemia, tumor stage III–IV, thoracotomy, operation time ≥ 2 h, intraoperative blood loss ≥ 200 mL, preoperative chemotherapy, and abnormal D-dimer levels.
Previous studies have consistently recognized advanced age as a risk factor for postoperative VTE in lung cancer patients (13, 16, 25, 31). However, the specific age threshold for risk stratification remains controversial. Our analysis demonstrated that patients aged 65 years or older had a significantly higher risk of VTE. This may be explained by age-related physiological decline, including diminished functional reserve, reduced muscle tone, endothelial dysfunction, and impaired venous compliance, all of which contribute to an elevated thromboembolic risk in the elderly surgical population (35). While some studies (13) have suggested smoking as a risk factor due to its role in vascular endothelial injury, platelet activation, increased blood viscosity, and slowed blood flow, thereby accelerating thrombosis (36), our meta-analysis did not find a statistically significant association between smoking history and VTE. We believe that the studies included might have only regarded smoking history as a binary variable of “present/absent,” failing to incorporate more precise indicators of exposure dose. Moreover, in the specific group of lung cancer patients, smoking itself is the primary causative factor (37). The baseline smoking rate among the study population was generally high, which might have weakened the effectiveness of the comparison between the groups. Similarly, although male sex has been linked to higher VTE incidence—possibly due to a higher prevalence of smoking and associated increases in blood viscosity with the long-term effect of nicotine in tobacco (21)—our results did not identify male sex as an independent risk factor.
Hyperlipidemia was confirmed as a significant risk factor for VTE after lung cancer surgery in this study. The underlying mechanism may involve vascular endothelial injury and enhanced platelet aggregation caused by high lipid levels. Elevated cholesterol and triglycerides can contribute to atherosclerotic plaque formation, narrowing the vascular lumen, impeding blood flow, and limiting postoperative mobility, thereby increasing thrombotic risk (38). Furthermore, advanced tumor stage (III–IV) was strongly associated with VTE, consistent with earlier reports such as that by Amer et al., who observed VTE incidences of 64.8% in stage III–IV patients compared to 34.2% in stage I–II patients (39). This may be attributed to cancer progression and metastasis exacerbating systemic hypercoagulability (20). Although some evidence suggests that lung adenocarcinoma carries a higher VTE risk compared to squamous cell carcinoma (40), our analysis did not find a statistically significant association between its pathological subtype and postoperative VTE.
Our study identified several surgery-related factors as significant contributors to VTE risk. Specifically, thoracotomy, an operation time ≥ 2 h, and intraoperative blood loss ≥ 200 mL were all independently associated with an increased incidence of VTE following lung cancer surgery. During lung cancer surgery, the clamping and manipulation of major blood vessels can cause trauma to local arteries and veins. Compared to video-assisted thoracic surgery, open thoracotomy inevitably leads to more extensive tissue damage, which elevates systemic stress levels and promotes the release of inflammatory factors. This inflammatory response can induce endothelial cell dysfunction, thereby activating the coagulation system and ultimately promoting thrombus formation (41). Consequently, lung cancer patients undergoing thoracotomy are at a higher risk of developing VTE. Prolonged operative time directly extends both anesthesia duration and immobilization period, which may cause vascular endothelial injury and alter hemodynamics, leading to reduced venous pressure and decreased blood flow velocity, thereby increasing the risk of thrombosis (42, 43). However, the findings of this study indicated that while an operative time of ≥2 h was a risk factor for VTE, a threshold of ≥3 h did not show statistical significance. This discrepancy may be attributed to the limited number of studies included. Increased intraoperative blood loss leads to hemoconcentration, and concomitant peripheral vasoconstriction slows blood flow, collectively promoting thrombosis (44). Additionally, prolonged bed rest after surgery can cause reduced and stagnant blood flow in the lower extremity veins, which may also elevate the risk of thrombosis (45).
Studies have shown that there is a statistically significant positive correlation between BMI and VTE (46). However, in oncology, there is a notable “obesity paradox” phenomenon (47). For lung cancer patients, obesity is associated with better postoperative prognosis and lower incidence. Patients with mild overweight may have a survival advantage when dealing with surgical stress due to better metabolic reserves and nutritional status (47, 48).
Preoperative chemotherapy was also identified as a significant risk factor in our study. Platinum-based agents, in particular, are known to enhance thrombin generation and reduce levels of natural anticoagulants such as proteins S and C. Many chemotherapeutic drugs can directly injure vascular endothelial cells, activate the coagulation system, and suppress fibrinolysis, collectively increasing thrombosis risk (49, 50). Finally, elevated D-dimer—a fibrin degradation product reflecting fibrinolytic activity—was confirmed as a risk factor in this study. It serves as an important biomarker in the diagnosis of thrombosis and pulmonary microvascular embolism (51), and our results support its value in predicting VTE after lung cancer surgery.
Limitations
5
This study has several limitations (1): Only Chinese and English publications were included, potentially overlooking relevant studies in other languages and introducing selection bias (2). Some risk factors (e.g., age ≥ 65 years old, operation time ≥ 2 h, operation time ≥ 3 h, hyperlipidemia, and intraoperative blood loss ≥200 mL) were analyzed based on a limited number of studies and small sample sizes. Due to the limited number of included studies, this may affect the stability of the combined effect values and statistical power. Therefore, the interpretation of the strength of association for these specific factors should be cautious (3). Variability in follow-up durations across the included studies may have affected the accuracy of postoperative VTE incidence estimates (4). Due to the limited availability of data, it was not feasible to evaluate all potential risk factors (5). Specific genetic mutations (e.g., ALK, EGFR, and KRAS) and related targeted therapies (such as EGFR-TKI inhibitors) may have distinct associations with thrombotic risk; however, due to insufficient reporting in the original studies, this aspect could not be incorporated into our analysis. Therefore, it is suggested that multi-center and large-sample epidemiological studies be carried out in the future to further clarify the related risk factors for VTE in patients after lung cancer surgery.
Conclusion
6
This meta-analysis identified the following significant risk factors for postoperative VTE in lung cancer patients: age ≥ 65 years, hyperlipidemia, advanced tumor stage (III–IV), thoracotomy, operation time ≥ 2 h, intraoperative blood loss ≥ 200 mL, abnormal D-dimer levels, and preoperative chemotherapy. Prior to scheduling surgery, clinicians should thoroughly evaluate whether patients exhibit these risk factors to mitigate the incidence of VTE. Future multi-center, large-sample epidemiological studies are recommended to further elucidate the risk factors associated with VTE in this patient population.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Bray F Laversanne M Sung H Ferlay J Siegel RL Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2024) 74:229–63. doi: 10.3322/caac.21834, 38572751 · doi ↗ · pubmed ↗
- 2Siegel RL Miller KD Fuchs HE Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. (2021) 71:7–33. doi: 10.3322/caac.21654, 33433946 · doi ↗ · pubmed ↗
- 3Wang J Yang Y Lu S Huang J Li S Chang H . Electroacupuncture combined with cisplatin induces an effective anti-tumor immune response by protecting chemotherapy-impaired bone marrow hematopoiesis in non–small cell lung cancer mice. Acupunct Herb Med. (2025) 5:229–45. doi: 10.1097/HM 9.0000000000000158 · doi ↗
- 4Zhang Y You P Liu R Lu Y Li J Lei Y . Artificial intelligence in clinical trials of lung cancer: Current and future prospects. Intell Oncol. (2025) 1:34–51. doi: 10.1016/j.intonc.2024.11.003 · doi ↗
- 5Wu S Zhuang A Huang G Zhao Z Zhan W Lei Y . A narrative review of the prediction of immunotherapy efficacy for treating NSCLC: An artificial intelligence perspective. Intell Oncol. (2025) 1:193–203. doi: 10.1016/j.intonc.2025.05.001 · doi ↗
- 6Ma X Han S Nie J . Diagnosis and Treatment Characteristics of Lung Cancer Patients with Venous Thromboembolism. Cancer Res Prev Treat. (2020) 47:335–9. doi: 10.3971/j.issn.1000-8578.2020.19.1243 · doi ↗
- 7Li Z Li F Han B Yu L. Clinical effect observation of unfractionated heparin versus low molecular weight heparin sodium in preventing venous thromboembolism in lung cancer patients. J Clin Med Pract. (2020) 24:51–4. doi: 10.7619/jcmp.202008013 · doi ↗
- 8Yu Y Zong L Zhang H Sheyhidin I Zhu H. Value of maximum amplitude of thrombus in thromboelastogram in predicting occurrence of venous thrombosis in patients after lung cancer surgery. Chin J Clin Thorac Cardiovasc Surg. (2022) 29:899–903. doi: 10.7507/1007-4848.202012010 · doi ↗